Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
02 12 2019
Historique:
received: 19 07 2018
accepted: 16 08 2019
pubmed: 21 8 2019
medline: 23 6 2020
entrez: 21 8 2019
Statut: ppublish

Résumé

Patients with paroxysmal nocturnal hemoglobinuria (PNH) have a clonal population of blood cells deficient in glycosylphosphatidylinositol-anchored (GPI-anchored) proteins, resulting from a mutation in the X-linked gene PIGA. Here we report on a set of patients in whom PNH results instead from biallelic mutation of PIGT on chromosome 20. These PIGT-PNH patients have clinically typical PNH, but they have in addition prominent autoinflammatory features, including recurrent attacks of aseptic meningitis. In all these patients we find a germ-line point mutation in one PIGT allele, whereas the other PIGT allele is removed by somatic deletion of a 20q region comprising maternally imprinted genes implicated in myeloproliferative syndromes. Unlike in PIGA-PNH cells, GPI is synthesized in PIGT-PNH cells and, since its attachment to proteins is blocked, free GPI is expressed on the cell surface. From studies of patients' leukocytes and of PIGT-KO THP-1 cells we show that, through increased IL-1β secretion, activation of the lectin pathway of complement and generation of C5b-9 complexes, free GPI is the agent of autoinflammation. Eculizumab treatment abrogates not only intravascular hemolysis, but also autoinflammation. Thus, PIGT-PNH differs from PIGA-PNH both in the mechanism of clonal expansion and in clinical manifestations.

Identifiants

pubmed: 31430258
pii: 123501
doi: 10.1172/JCI123501
pmc: PMC6877298
doi:
pii:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Glycosylphosphatidylinositols 0
Inflammasomes 0
Membrane Proteins 0
phosphatidylinositol glycan-class A protein 0
Complement System Proteins 9007-36-7
eculizumab A3ULP0F556

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5123-5136

Commentaires et corrections

Type : CommentIn

Références

J Biol Chem. 1997 Jun 20;272(25):15834-40
pubmed: 9188481
Mol Immunol. 2004 Jun;41(2-3):103-11
pubmed: 15159055
Blood. 2005 Dec 1;106(12):3699-709
pubmed: 16051736
Mol Biol Cell. 2003 May;14(5):1780-9
pubmed: 12802054
Neurogenetics. 2014 Aug;15(3):193-200
pubmed: 24906948
Immunol Rev. 2004 Apr;198:185-202
pubmed: 15199963
Br J Haematol. 2003 Oct;123(1):173-6
pubmed: 14510962
Blood. 2008 Feb 15;111(4):2132-41
pubmed: 18063752
Nat Commun. 2018 Jan 26;9(1):405
pubmed: 29374258
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Br J Haematol. 2013 Jul;162(1):62-73
pubmed: 23617322
Brain Dev. 2018 Jan;40(1):53-57
pubmed: 28728837
BMJ Case Rep. 2018 Sep 27;2018:null
pubmed: 30262533
Genes (Basel). 2016 Nov 29;7(12):
pubmed: 27916860
J Biol Chem. 2012 Feb 24;287(9):6318-25
pubmed: 22228761
Front Genet. 2018 May 08;9:153
pubmed: 29868109
FASEB J. 2017 Jun;31(6):2439-2445
pubmed: 28246166
J Med Genet. 2013 Aug;50(8):521-8
pubmed: 23636107
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7938-43
pubmed: 8755581
J Clin Invest. 2014 Oct;124(10):4529-38
pubmed: 25244093
Science. 1993 Feb 26;259(5099):1318-20
pubmed: 7680492
Oncogene. 2000 Aug 10;19(34):3902-13
pubmed: 10952764
J Immunol. 2014 Mar 15;192(6):2837-45
pubmed: 24554772
Science. 1995 Jul 7;269(5220):89-92
pubmed: 7541557
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
J Immunol. 2013 Aug 1;191(3):1006-10
pubmed: 23817414
J Biol Chem. 1998 Jan 23;273(4):2355-60
pubmed: 9442081
Nat Clin Pract Rheumatol. 2008 Sep;4(9):481-9
pubmed: 18665151
J Biol Chem. 1996 Feb 2;271(5):2448-54
pubmed: 8576206
Proc Natl Acad Sci U S A. 2004 May 11;101(19):7341-6
pubmed: 15123827
N Engl J Med. 2006 Sep 21;355(12):1233-43
pubmed: 16990386
EMBO J. 2002 Oct 1;21(19):5047-56
pubmed: 12356721
EMBO J. 2001 Aug 1;20(15):4088-98
pubmed: 11483512
Cell. 1997 Jan 10;88(1):1-4
pubmed: 9019395
J Exp Med. 2001 Feb 5;193(3):393-7
pubmed: 11157059
Cell. 1993 May 21;73(4):703-11
pubmed: 8500164
Semin Hematol. 1989 Jul;26(3):201-7
pubmed: 2675316
FEBS Lett. 2002 Feb 13;512(1-3):249-54
pubmed: 11852090
J Biol Chem. 2002 Dec 20;277(51):49403-7
pubmed: 12384495
Mol Genet Metab. 2015 Jun-Jul;115(2-3):128-140
pubmed: 25943031
Blood. 2013 Aug 15;122(7):1312-5
pubmed: 23733340
J Biol Chem. 2019 Mar 29;294(13):5038-5049
pubmed: 30728244
Immunity. 2017 Jun 20;46(6):943-956
pubmed: 28636961
Science. 2016 Jun 17;352(6292):aad1210
pubmed: 27313051
Br J Haematol. 2001 Nov;115(2):360-8
pubmed: 11703336
Eur J Immunol. 2014 Dec;44(12):3669-79
pubmed: 25229885
Eur J Hum Genet. 2017 Jun;25(6):669-679
pubmed: 28327575
J Clin Invest. 2013 May;123(5):2169-82
pubmed: 23543057
Immunology. 1994 May;82(1):34-41
pubmed: 7519172
Parasitology. 1994 Feb;108 ( Pt 2):139-45
pubmed: 7512710
Nat Rev Dis Primers. 2017 May 18;3:17028
pubmed: 28516949
Br J Haematol. 2018 Sep;182(6):758-776
pubmed: 29974931
Blood. 1992 Mar 15;79(6):1385-92
pubmed: 1547338
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
Genet Med. 2019 Oct;21(10):2216-2223
pubmed: 30976099
Acta Neuropathol. 1995;89(3):239-47
pubmed: 7754744
Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(4):130-43
pubmed: 24727937
Am J Clin Pathol. 2000 Sep;114(3):459-66
pubmed: 10989647
Blood. 2006 Dec 15;108(13):4232-6
pubmed: 16940417

Auteurs

Britta Höchsmann (B)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.
Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm, Germany.

Yoshiko Murakami (Y)

Research Institute for Microbial Diseases and.
WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.

Makiko Osato (M)

Research Institute for Microbial Diseases and.
Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Alexej Knaus (A)

Institute for Genomic Statistics and Bioinformatics, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.

Michi Kawamoto (M)

Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan.

Norimitsu Inoue (N)

Department of Tumor Immunology, Osaka International Cancer Institute, Osaka, Japan.

Tetsuya Hirata (T)

Research Institute for Microbial Diseases and.

Shogo Murata (S)

Research Institute for Microbial Diseases and.
Department of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.

Markus Anliker (M)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.

Thomas Eggermann (T)

Institute for Human Genetics,Medical Faculty, RWTH University Aachen, Aachen, Germany.

Marten Jäger (M)

Department of Medical Genetics, Charite Hospital, University of Berlin, Berlin, Germany.

Ricarda Floettmann (R)

Department of Medical Genetics, Charite Hospital, University of Berlin, Berlin, Germany.

Alexander Höllein (A)

MLL Muenchner Leukaemielabor GmbH, Munich, Germany.

Sho Murase (S)

Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan.

Yasutaka Ueda (Y)

Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Jun-Ichi Nishimura (JI)

Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Yuzuru Kanakura (Y)

Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Nobuo Kohara (N)

Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan.

Hubert Schrezenmeier (H)

Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.

Peter M Krawitz (PM)

Institute for Genomic Statistics and Bioinformatics, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany.

Taroh Kinoshita (T)

Research Institute for Microbial Diseases and.
WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH